The clinical study phase IIb with LT-02 in patients who suffer from active ulcerative colitis was successfully completed.
This phase IIb study was performed with support from Dr. Falk Pharma GmbH, Freiburg, Germany.
Following a co-development and option-agreement Dr. Falk will assume full responsibility for the further development and commercialization of LT-02 in Europe.
The pivotal Phase III clinical trial in ulcerative colitis has started in Europe in June of 2014
For further information please contact:
DR. FALK PHARMA GmbH
|0049 / 761 / 1514-0
0049 / 761 / 1514-321